Background: Inhaled endotoxin is known to induce airway inflammation, causing bronchial hyperreactivity. Objective: We characterized the response to lipopolysaccharide-inhalation by measuring exhaled nitric oxide (eNO) and inflammatory mediators. Patients and Methods: A total of 43 adult volunteers (13 asthmatics, 30 healthy controls) inhaled stepwise LPS every 30 min up to a cumulative dose of 100 µg (2.5, 10.5, 42, 45 µg). After each provocation and up to 24 h later, FEV 1 was determined; the procedure was stopped when FEV 1 declined more than 12.5%. We measured eNO, leucocytes, eosinophils, polymorphonuclear neutrophils (PMNs), C-reactive protein (CrP), lipopolysaccharide binding protein (LBP), eosinophilic cationic protein (ECP), leucotriene B4 (LTB4), thromboxane B2 (TXB2), and body temperature. Results: Initial eNO values were higher in asthmatics (P < 0.01), but only increased in an asthmatic subgroup. Marked differences were observed in the systemic response to LPS inhalation. Significant increases were found for CrP, LBP, and PMNs. There was no correlation between FEV 1 decrease and basal eNO levels. Conclusions: Inhalation of endotoxin was followed by clinical and laboratory signs of systemic inflammation, with asthmatics responding to the challenge similar as healthy subjects. Bronchial eNO increased only temporarily in asthmatics.
INTRODUCTION
In occupational medicine, endotoxin has been implicated as an etiological agent in the induction of acute and chronic respiratory symptoms, including reversible airway obstruction and chronic airway disease. 1, 2 Endotoxin (lipopolysaccharide; LPS) is ubiquitous and can be ingested from the environment via inhalation of dust or from contaminated water. As a constituent of the outer membrane of Gram-negative bacterial cells, it is a prototypic microbial trigger that stimulates innate immunity. 3, 4 The resultant inflammatory responses are essential in early host defence, but may also contribute to later and/or chronic organ injury.
LPS inhalation causes a mild, dose-dependant airway response, 5 and potentially induces bronchial hyper-reactivity (BHR). 6, 7 Other studies showed a relationship between endotoxin in house dust and the severity of allergic asthma. 8, 9 Previous investigations in healthy subjects who inhaled endotoxin revealed characteristics related to an inflammation in the airways such as dry cough, narrowing of the airways after an acute exposure, and increased airway responsiveness. [10] [11] [12] Thus, volunteers showed a decrease in FEV 1 and symptoms such as chest tightness, fever, headache, joint and muscle pain, nausea, and fatigue after LPS-inhalation. Levels of eNO are increased in atopy, bronchial asthma and after allergen challenge, and decrease rapidly after corticosteroids. 13, 14 Consequently, eNO is suggested as a marker of allergic inflammation and recent allergen exposure. 15 Data on eNO measurement after endotoxin inhalation in humans are scarce. An animal study revealed an increase of eNO following systemic application of LPS in rats, 16 suggesting a late-phase type of systemic inflammatory response. Endotoxin might stimulate nitric oxide (NO) synthesis, either directly or through the release of secondary mediators. 17 A 3-fold significant increase of eNO over 6 h following an inhalation of 60 µg of purified LPS had been seen in eight subjects with stable BHR administered endotoxin. 18 Five of these subjects reported chest tightness and cough after the LPS inhalation. In contrast, Sundblad et al. 19 did not find a comparable increase of eNO in healthy volunteers working in a swine house. An excellent marker for LPS-triggered inflammation is the LPS binding protein (LBP), which increases after LPS inhalation. 12 LBP is a protein mainly synthesized in the liver and induced by dendritic cell presentation. It binds the lipid-A portion of LPS to form a high-affinity LBP/LPS complex, enhancing the acute and chronic response to LPS. To understand and clarify the mode of action of endotoxin on mediator production, we measured eNO in comparison to LBP, PMNs, and CrP in experimental LPS inhalation. Additionally, cyclooxygenase and lipoxygenase pathways are involved in the induction of LPS derived lung inflammation. 20, 21 Thus, we also determined their stable protein metabolites LTB4 and TXB2.
PATIENTS AND METHODS

Subjects
We examined 30 healthy non-smoking adult volunteers and 13 asthmatics monoallergic to house dust mite as proven by inhalative allergen provocation. All came from an urban background, none of them had a pet in the household. Exclusion criteria were any administration of anti-inflammatory or antibiotic drugs 3 weeks prior to the study entrance, acute cardiac or pulmonary disease within the last 6 weeks, allergies and other chronic diseases, occupational exposure to LPS, or pregnancy. After written informed consent was obtained, all subjects were screened with spirometry, metacholine challenge, and skin-prick testing with common aero-allergens. Since allergic and/or asthmatic subjects are known to have higher and more variable NO-values, 22 only those with normal spirometry, without response to metacholine, and healthy subjects with skin prick tests negative to common allergens were included. Guidelines for Good Clinical Practice, German Drug Act, and human experimentation guidelines of the Declaration of Helsinki/Hong Kong were followed in the conduct of clinical research. Our selection criteria and exposure protocol were reviewed by the local Ethics Committee for Scientific Research.
Endotoxin and inhalation challenge protocol
Solutions of endotoxin for inhalation were prepared according to a protocol using lyophilized Escherichia coli LPS (E. coli O26:B6, Sigma-Aldrich Pharmaceuticals, gel-filtrated, chromatographed, and γ-ray sterilized) from fresh vials. 12 Solutions of LPS were resuspended in sterile 0.9% saline solution at a pH of 7.0 and filtered. Subjects were exposed in a single-blinded fashion by inhalation of sterile saline 0.9% followed 10 min later by increasing concentrations of LPS every 30 min, according to the following schedule: 2.5 µg, 10.5 µg, 42 µg, 45 µg. Thus, the entire protocol delivered a total cumulative dose of 100 µg of LPS. 10 The solutions were delivered via a Medic-aid nebulizer and the aerosol provocation system APS powered by compressed air (all by Viasys Inc., Wuerzburg, Germany).
Baseline spirometry (FEV 1 ) was recorded before and after inhalation of saline, then before and after each inhalation of LPS (after 10, 30, 60, 90, 120 min, and after 6, 8, and 24 h). Clinical monitoring accompanied each LPS provocation for at least 8 h, and then the subjects could leave the hospital remaining in touch via telephone with a physician involved in the study. Body temperature was taken before the saline inhalation, after every single LPS-provocation, and 6, 8, and 24 h after the start of the challenge. A significant change in lung function was defined as a FEV 1 decrease of at least 12.5% from baseline. The challenge test was stopped when any of the following criteria were met: (i) the FEV 1 decreased at least 12.5% from baseline; (ii) body temperature increased more than 0.5°C from baseline; (iii) occurrence of acute clinical complaints (e.g. headache, dyspnoea), and (iv) a cumulative dose of 100 µg LPS had been achieved.
Assignment of clinical phenotype
In accordance with the relevant literature, we categorized our study subjects depending on their response to inhalative LPS. [10] [11] [12] Whilst other studies used FEV 1 ≥ 20% as threshold for a significant airway response, we decided to take a more conservative level which encompassed higher safety for our volunteers. Subjects with a decrease of FEV 1 ≥ 12.5% were labelled as 'sensitive', the others as 'non-sensitive'. This classification was based on our prior clinical experience.
Exhaled NO was determined using a NO-analyzer (NIOX ® , Aerocrine Inc., Sweden) according to the criteria of the American Thoracic Society 23 before starting any inhalation and 30 min, 1, 2, 4, 6, 8, and 24 h after LPS inhalation. In order to control for intrasubject variability, the mean values of three consecutive measurements were taken.
Before and 24 h after inhalation, whole blood was collected for analysis of WBCs, PMNs, monocytes, eosinophils, ECP, CrP, LBP, LTB4, and TXB2. Blood cells were determined using a Coulter Counter (Beckmann Inc., USA). After centrifugation (1800 rpm) the resulting serum was stored at -80°C until testing. Serum samples were analyzed fluorometrically for ECP and LBP using a two-sided chemiluminescent test (Immulite ® DPC, Bad Nauheim, Germany). CrP was determined with a nephelometer. LTB4 and TXB2 were analyzed using commercial ELISA kits (R&D Systems Inc., Minneapolis, MN, USA).
Statistical analysis
Data analysis was performed using the software package SPSS v.11.0 (SPSS Inc., Chicago, IL, USA). All values are expressed as medians and ranges. Significance was defined as P < 0.05. In analyses where measurements were performed only twice, the non-parametric, Wilcoxon test was performed. Correlation analysis was performed using Pearson's correlation coefficient. Repeated eNO measurements were calculated by one-way ANOVA, testing of relationship between eNO and FEV 1 by multivariate analysis.
RESULTS
Patients and lung function
Demographic data and clinical reactions upon LPSinhalation are shown in Table 1 . All subjects were young adults; physical data were within normal ranges. During LPS inhalation, among the healthy subjects 12 were categorized as 'sensitive' and 18 as 'non-sensitive' (Fig. 1 ). Among asthmatics, 6 were 'sensitive' and 7 'non-sensitive'. Distribution of gender differed slightly. In healthy subjects, the male:female ratio was 1:1 in sensitives, whereas in non-sensitives it was 1:3.5. Corresponding values were 1:1 and 1:2.9 in asthmatics. Sensitive subjects experienced a significant fall in FEV 1 60 min after inhalation, reaching a maximum after 90 min, and lasting for 8 h whereas asthmatics decrease after an average of 90 min, reaching their maximum after 2 h. A similar amount (about 14%) demonstrated mild clinical responses to LPSinhalation. All complaints resolved within 6 h.
Exhaled NO and markers of systemic inflammation
As shown in Table 2 , in healthy subjects CrP, leucocytes, PMNs, and LBP increased after stimulation, suggesting systemic inflammation. When comparing sensitive with non-sensitive subjects, only PMNs were significantly higher in sensitive subjects before LPS-stimulation (2.75 per nl versus 2.45 per nl; P = 0.01). Leucocytes, monocytes, and CrP were distributed equally. LTB4 and TXB2 decreased slightly, with the later reaching significance in sensitive and non-sensitive healthy subjects (P < 0.05, each). In asthmatics, CrP, LBP, leucocytes, and PMNs increased significantly (Table 3 ). LTB4 and TXB2 decreased also in asthmatics, but significance was only achieved for TXB2 in sensitive individuals. Twenty-four hours after LPS inhalation, in neither group could an increase of eNO be observed (Fig. 2) . In asthmatics, Fig. 1 . Maximum drop in FEV 1 following LPS-inhalation in sensitive versus non-sensitive subjects (n = 43). Individual values and medians. There were no statistical significant differences between asthmatic and healthy subjects. there was a trend to higher eNO values in non-sensitive subjects (15.0 versus 35.1 ppb; P = 0.086). We observed an increase over 6 h, returning to initial values within 24 h. The increase after 6 h was significant from baseline values in sensitive asthmatics (Fig. 2) ; when pooling all values from asthmatics, this result persisted (data not shown). Overall, average eNO values were higher in non-sensitive asthmatics than in sensitive ones. Logarithmic transformation of eNO values was not necessary, since the range of the detected values did not require this. In either group, LBP correlated negatively with eNO -r = -0.71 in sensitives, and r = -0.07 in nonsensitives. Correlation for CrP was r = 0.25 for sensitives and r = --0.11 in non-sensitives. The one-way ANOVA for repeated eNO measurement revealed no significant change of values between the different times of testing (P = 0.224). Multivariate testing of eNO versus FEV 1 also did not detect a significant relationship between the two variables (P = 0.585).
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Markers of eosinophilia
Overall, no changes of ECP were detected. Only in the subgroup analysis could a significant increase of ECP be observed in sensitive healthy and non-sensitive asthmatic subjects (Tables 2 and 3 ). There was no significant change of eosinophils in either group.
Body temperature
In sensitive healthy subjects, temperature increased from a median of 36 37 .3°C (range, 35.9-37.9°C) after 5-9 hours (P < 0.001, each). Values returned to baseline after 24 h in all groups. Besides the temporal pattern, statistical comparison revealed no differences between the groups.
DISCUSSION
In animal models of sepsis, NO was found in exhaled air and was suggested as a marker of airway inflammation. 24 In particular, the NO synthetase NOS 2 participated in the acute inflammatory response to LPS by multiple mechanisms: involvement in pro-inflammatory cytokine sig-nalling and alteration of the expression of various genes that affect inflammatory-immune responses to LPS. 25 Systemic application of LPS induced NO production by up-regulation of the pulmonary inducible NO-synthetases (iNOS). 26 Inhibitors of iNOS (e.g. L-NAME, dexamethasone) were able to reduce iNOS-mRNA expression, eNO and pulmonary oedema. Various body fluids analyzed after LPS inhalation revealed an increased influx of mainly neutrophils into the airways, resulting from a production of chemotactic factors from activated macrophages (e.g. TNF-α, IL-1β, IL-8). 27 In order to gain further insight into the mechanism of LPS-induced airway disease, we measured eNO in comparison to inflammatory mediators after experimental LPS inhalation. In our healthy subjects and within 24 h following stimulation, exhaled nitric oxide values of all individuals remained normal (< 20 ppb), whilst marked differences were observed in their systemic response to LPS inhalation. In our asthmatics and irrespective of airway response, eNO increased further from initially elevated values after 6 h, and normalized after 24 h as well. When stratifying the asthmatics for airway response, non-sensitive subjects had significantly higher eNO values, but increased less than sensitive individuals. These findings are in accordance with experimental data obtained from guinea pigs. Here, nitric oxide values increased 4 h after LPS inhalation and normalized after 24 h. 28 In all study subjects, significant increases of LBP, CrP, and neutrophils were observed, suggesting neutrophilic inflammation. Thus, ECP remained unchanged overall. Only when stratifying for airway response, some differences could be found. This might be explained by polymorphisms in the genes regulating TLR4 and CD14. 29 Further genetic analysis of our study subjects might resolve this observation.
Thromboxane B2 (TXB2) and leucotriene B4 (LTB4) are known as mediators of transendothelial neutrophilic migration in LPS-induced acute lung injury. Interestingly, in our study, TXB2 and LTB4 decreased slightly in all group within 24 h. This parallels observations in rats, where intratracheal LPS installation resulted in no changes of LTB4 over 6 h. 30 Also, another study confirmed our observation in human whole blood cells, where LTB4 returned to baseline values after 24 h following LPS-provocation. 31 The nature and mechanism of LPS-induced airway disease are not completely clarified. Besides Toll-likereceptors, CD-14, and lipoproteins, the important role LBP has been demonstrated recently. 32 LBP, which is a critical molecule in the determination of inflammatory response following LPS inhalation, clearly enhances the acute and chronic response to LPS, resulting potentially in organ damage. 33 Our results are, in part, in contrast to previous studies which demonstrated acute airway inflammation as well as systemic effects upon inhalation of endotoxin. 34, 35 Instead, we found no correlation between eNO and LBP. Less production of LBP was also associated with less CrP (r = 0.46; data not shown). Our findings might suggest that individuals reacting with early bronchial inflammation may inhibit systemic reaction to LPS, with early bronchoconstriction as a potential physiological mechanism of protection against threatening exposure. Also in animal models, it was shown that early airway response to inhaled LPS was associated with no increase of bronchial NO up to 24 h, whereas an LPS-induced airway hyporeactivity after 48 h was associated with an overproduction of NO. 28 In contrast to another study, in our population women were less likely to respond to LPS inhalation, despite receiving a relatively higher LPS dose, as they were shorter and lighter. 10 This observation could be confirmed in asthmatics with the constraint of overall small sample sizes. Occupational studies with larger populations might elucidate this discrepancy. The response pattern of our study subjects was also different from subjects with stable BHR, who demonstrated a 3-fold increase of eNO over 6 h following LPS inhalation. 18 Our diverse observations might be related to different levels of LBP in asthmatic versus non-asthmatic subjects, especially in our sensitive asthmatics following LPS inhalation. LBP and soluble CD14 levels were markedly elevated in another study in broncho-alveolar lavage fluids obtained from asthmatic subjects after allergen challenge compared to those in normal controls. 36 It is tempting to speculate that LBP present in the lung could stimulate alveolar phagocytosis of LPS and trigger the release of pro-inflammatory mediators. This might augment the pulmonary inflammation and airway reactivity associated with allergic asthma. In keeping with this, LBP-deficient mice did not develop substantial Ag-induced airway reactivity, whereas wild-type mice developed marked bronchoconstriction following aerosol Ag-sensitization. Similarly, production of NOsynthase-2-protein and the NO catabolite peroxynitrite was dramatically higher in the lungs of wild-type mice following challenge compared with LBP-deficient mice. 37 The question remains, whether the degree of airway response to LPS inhalation is related to inflammatory reaction and clinical symptoms. Kline et al. 10 who exposed volunteers to increasing doses of LPS up to a cumulative dose of 41.5 µg, classified their subjects as 'sensitive' (10.5%), 'intermediate' (69.7%), or 'hyporesponsive' (14.5%), with the first group decreasing with their FEV 1 by 20% after inhaling < 6.5 µg, and the last group declining < 10% before reaching a cumulative dose of 41.5 µg LPS. In a subgroup-analysis, the authors found significantly lower IL-6 and IL-8 in peripheral blood monocytes in the hyporesponsive group compared to the sensitive group. 10 In keeping with these data, we also found two clinical phenotypes; 40% of our healthy subjects declined with their FEV 1 , whereas 60% tolerated a cumulative LPS-dose of 100 µg LPS. Although our subjects tolerated higher doses of inhaled LPS, we found a similar ratio of patients showing airflow obstruction and clinical symptoms.
It is interesting to note that sensitive patients show a later rise of body temperature and fewer clinical complaints (data not shown). This implies the possibility that airflow limitation due to LPS inhalation is not only a symptom associated with airway obstruction, but may be also a natural protective mechanism avoiding the inoculation of higher amounts of LPS into the organism.
Our present study is significant in that we assessed the role of LBP and eNO as markers for bronchial inflammation following LPS inhalation. Clinical and laboratory signs of neutrophilic systemic inflammation were found, but only significant increases of bronchial eNO in LPS-sensitive asthmatics. This is in accordance with an increased NO production in allergic inflammation following allergen exposure. 38 In non-atopic subjects, monitoring of eNO appears not to be a suitable tool for measuring endotoxin-induced inflammation.
